Breast cancer stage III+2
Not recruitingStudy on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound
Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound
- Disease:Breast cancer stage IIIBreast cancer stage IV+1
- Substances:CeralasertibDurvalumab+1
Italy- Participants:18–64 years · 65+ years
- Substances:Ceralasertib
- Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets














